Abstract
The application of gene therapy in cancer treatment is limited by non-specific targeting. In the present study, we constructed a recombinant plasmid, containing a carcinoembryonic antigen (CEA) promoter and double suicide genes thymidine kinase (TK) and cytosine deaminase (CD), henceforth referred to as pCEA-TK/CD. Our results showed that the CEA promoter can specifically drive target gene expression in CEA-positive lung cancer cells. In the presence of prodrugs 5-flucytosine and ganciclovir, pCEA-TK/CD transfection decreased inhibitory concentration 50 and increased apoptosis and cyclomorphosis. Our result suggests that gene therapy using pCEA-TK/CD may be a promising new approach for treating lung cancer.
Crown Copyright © 2011. Published by Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Apoptosis / drug effects
-
Apoptosis / genetics
-
Carcinoembryonic Antigen / genetics*
-
Cell Cycle / drug effects
-
Cell Cycle / genetics
-
Cell Line, Tumor
-
Cytosine Deaminase / biosynthesis
-
Cytosine Deaminase / genetics*
-
Cytosine Deaminase / metabolism
-
Flucytosine / pharmacology
-
Ganciclovir / pharmacology
-
Gene Expression / drug effects
-
Gene Expression / genetics
-
Genes, Transgenic, Suicide*
-
Genetic Therapy / methods
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / enzymology
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / therapy*
-
Plasmids / genetics
-
Prodrugs / pharmacokinetics
-
Prodrugs / pharmacology
-
Promoter Regions, Genetic
-
Thymidine Kinase / biosynthesis
-
Thymidine Kinase / genetics*
-
Thymidine Kinase / metabolism
-
Transfection / methods
Substances
-
Carcinoembryonic Antigen
-
Prodrugs
-
Flucytosine
-
Thymidine Kinase
-
Cytosine Deaminase
-
Ganciclovir